clinical trial · NCT07177872
A Long-term Efficacy and Safety of NTQ5082 Capsules
Nanjing Chia-tai Tianqing Pharmaceutical·phase3·not yet recruiting·n = 78
Paroxysmal Nocturnal HemoglobinuriaNTQ5082 capsules 200 mg
brief summary
NTQ5082 capsules are a small molecule CFB inhibitor. This study is a multicenter, open-label study evaluating the long-term efficacy and safety of NTQ5082 capsules in the treatment of patients with paroxysmal nocturnal hemoglobinuria
started
Jun 1, 2026
primary completion
Jun 1, 2028
completion
Jun 1, 2028
last updated
Sep 17, 2025
official title
A Multicenter, Open-label Study Evaluating the Long-term Efficacy and Safety of NTQ5082 Capsules in the Treatment of Patients With Paroxysmal Nocturnal Hemoglobinuria
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol